Chlamydia pneumoniae TWAR is a newly recognized Chlamydia species that is a pathogen of respiratory tract infection. To clarify the endemic status of C. pneumoniae in Japan, we evaluated the incidence of C. pneumoniae antibody in 1,330 serum samples (660 from outpatients, 600 from normal individuals, and 70 from cord blood). The antibody titer was determined by a microimmunofluorescence test by using the elementary body of C. pneumoniae TW-183 as the antigen. Immunoglobulin G antibody titers of 1:32 or higher were regarded as evidence of past infection. The detection rate of C. pneumoniae antibody rapidly increased in subjects between the ages of 4 and 7 years, reached 44% in subjects between the ages of 8 and 11 years, and was about 50% in older subjects. The rate did not differ between healthy subjects and outpatients. These results suggest that C. pneumoniae infection is highly endemic in Japan as it is in Western countries. However, the antibody prevalence was high in the low age groups in Japan compared with that in Western countries.
Chlamydia pneumoniae was recently recognized as the third Chlamydia species (5) , in addition to Chlamydia trachomatis, which causes trachoma, sexually transmitted diseases, and neonatal and infantile pneumonia and conjunctivitis, and Chlamydia psittaci, which causes psittacosis. C. pneumoniae was initially regarded as a subspecies of C.
psittaci (6, 10, 16) but was classified in 1989 as a new Chlamydia species (5) on the basis of the characteristic morphology of the elementary body (3) , results of evaluation with monoclonal antibody, and DNA homology (2) .
Since C. pneumoniae has been reported (6) to cause pneumonia and bronchitis, this organism has attracted attention as a pathogen of respiratory tract infections (7, 9, (11) (12) (13) 15) . However, little is known about its infection route or clinical picture (1, 8, 17) .
We evaluated the prevalence of C. pneumoniae antibody in healthy subjects and outpatients in Japan.
Specimens C. pneumoniae antibody prevalence. Table 1 shows the age-related incidence of C. pneumoniae antibody. Among the outpatients (group 1), the antibody detection rate rapidly increased in subjects between the ages of 4 and 7 years, reached 44% in subjects between the ages of 8 and 11 years, and was about 50% in older subjects. The antibody was positive in 51% of the samples from cord blood; this rate was similar to that in the maternal age group (20 to 30 years old). In healthy subjects aged 16 years or older (group 2), the antibody was present in 52%. Antibody to C. pneumoniae in subjects less than 20 years old was present in 98 (35.5%) of 276 males and 84 (37.5%) of 224 females. In subjects over 20 years old, C. pneumoniae antibody was present in 193 (52.2%) of 370 males and 175 (44.9%) of 390 females. Therefore, no relationship was found between gender and incidence of C. pneumoniae antibody. Table 2 shows the distribution of C. pneumoniae antibody titers of 1:32 or higher in group 1. Antibody titers of 1:256 or higher were observed in 11% of the outpatients that tested positive for antibody.
Recent respiratory tract infections in outpatients with high C. pneumoniae antibody titers. We were able to take the medical history for the previous 3 months in 9 of 11 outpatients who had a C. pneumoniae titer of 1:521 or higher, which is considered to indicate a recent infection (8) . Of these nine outpatients, three had developed pneumonia. Two had suffered from Mycoplasma pneumoniae infection and the other had had pneumonia of unknown origin (including C. pneumoniae) during the previous 3-month period. Three of the remaining six outpatients had developed coldlike symptoms and tonsillitis, but the other three had been healthy.
Recently, Grayston et al. (8) b Group 2 consisted of 300 serum samples from healthy subjects and 300 serum samples from blood donors in Hiroshima.
' A titer of 1:32 or higher in the IgG serum fraction, measured by the microimmunofluorescence test, was considered positive. titers of 1:16 or higher indicate past infection. However, C. pneumoniae antibody titers of 1:32 or higher have been reported in several populations around the world (14, 18), so we considered a serum titer of 1:32 or higher as positive in order to compare our results with earlier studies. The detection rate of C. pneumoniae antibody increased rapidly in subjects between the ages of 4 and 7 years, and 44% of subjects aged 8 to 11 years already showed the antibody. In subjects aged 12 years or older, the antibody detection rate was about 50%. The detection rate did not differ between outpatients and healthy controls. The rate in the adults was similar to that (45%) in 196 male patients with sexually transmitted diseases in Japan (18) . The prevalence of C. pneumoniae antibody began to increase in subjects between the ages of 4 and 7 years in several limited populations in Western countries (4, 18) . Compared with our subjects, this increase was more gradual and the rate continued to increase even in adults, reaching about 50% in subjects between the ages of 30 and 40 years. The rapid increase in the antibody detection rate in children in Japan, which is as developed as and more densely populated than Western countries in the present study and in other studies in Asia (4, 15, 18) , suggests that C. pneumoniae is more endemic in Asia than in Western countries. Saikku et al. (15) suggested that the Table 1. prevalence of C. pneumoniae is associated with population density.
As a diagnostic criterion for recent infection, Grayston et al. used a C. pneumoniae IgG antibody titer of 1:512 or higher (8) . However, our investigation of the medical history for the 3 months preceding serum collection outpatients with an antibody titer of 1:512 or higher found diseases such as pneumonia in only some of them. Actually, two of the outpatients had suffered from pneumonia caused by M. pneumoniae. Thus, caution is needed in diagnosing pneumonia in patients with a high C. pneumoniae IgG antibody titer. A fourfold or greater increase in the IgG antibody titer in paired serum samples or confirmation of IgM antibody seems to be necessary. Although the association of C. pneumoniae infection with pneumonia and bronchitis has been suggested, the low incidence of these diseases in patients with high antibody titers suggests only that mild coldlike symptoms and mild reinfection frequently occur (8) .
